1. Home
  2. CSV vs CBIO Comparison

CSV vs CBIO Comparison

Compare CSV & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carriage Services Inc.

CSV

Carriage Services Inc.

HOLD

Current Price

$32.21

Market Cap

491.1M

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$14.14

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSV
CBIO
Founded
1991
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
491.1M
537.5M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
CSV
CBIO
Price
$32.21
$14.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
★ $59.00
$26.67
AVG Volume (30 Days)
124.3K
★ 376.0K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
★ 0.92%
N/A
EPS Growth
★ 54.76
N/A
EPS
★ 1.61
N/A
Revenue
★ $417,440,000.00
$18,500.00
Revenue This Year
$7.35
N/A
Revenue Next Year
$3.87
$279.20
P/E Ratio
$19.86
★ N/A
Revenue Growth
★ 3.28
N/A
52 Week Low
$30.11
$8.72
52 Week High
$52.10
$27.41

Technical Indicators

Market Signals
Indicator
CSV
CBIO
Relative Strength Index (RSI) 43.83 31.82
Support Level N/A $9.95
Resistance Level $35.17 $18.53
Average True Range (ATR) 0.84 1.41
MACD 0.15 -0.63
Stochastic Oscillator 59.69 7.61

Price Performance

Historical Comparison
CSV
CBIO

About CSV Carriage Services Inc.

Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: